These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24535551)

  • 1. Very late HCV relapse following triple therapy for hepatitis C.
    Barreiro P; Vispo E; Maida I; Aguilera A; Fernández-Montero JV; de Mendoza C; Labarga P; Soriano V
    Antivir Ther; 2014; 19(7):723-4. PubMed ID: 24535551
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis C virus (HCV) therapies special thematic issue: call for papers.
    Georg GI; Wang S
    J Med Chem; 2013 Jan; 56(2):387. PubMed ID: 23294104
    [No Abstract]   [Full Text] [Related]  

  • 3. New hepatitis C therapies.
    Pawlotsky JM
    Semin Liver Dis; 2014 Feb; 34(1):7-8. PubMed ID: 24782253
    [No Abstract]   [Full Text] [Related]  

  • 4. Twelve week post-treatment undetectable hepatitis C virus (HCV)-RNA by PCR assay predicts a sustained virological response to anti-HCV therapy independently from immunological status of the infected patients.
    Donato MF; Bastiampillai AJ; Manini M; Monico S
    J Antimicrob Chemother; 2013 Apr; 68(4):974-5. PubMed ID: 23221629
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Existing and future therapeutic options for hepatitis C virus infection.
    Bretner M
    Acta Biochim Pol; 2005; 52(1):57-70. PubMed ID: 15827606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of antiviral therapy in the long-term outcome of recurrent hepatitis C virus infection following liver transplantation.
    García-Reyne A; Lumbreras C; Fernández I; Colina F; Abradelo M; Magan P; San-Juan R; Manrique A; López-Medrano F; Fuertes A; Lizasoain M; Moreno E; Aguado JM
    Transpl Infect Dis; 2013 Aug; 15(4):405-15. PubMed ID: 23725370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HCV genotype 5: epidemiology and spread of an uncommon genotype.
    Verbeeck J; Peigue-Lafeuille H; Ross RS; Abergel A; Nevens F; Van der Merwe S; Van Ranst M; Henquell C
    J Clin Virol; 2008 Feb; 41(2):170-1. PubMed ID: 18069057
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
    Cristina J; del Pilar Moreno M; Moratorio G
    Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tailored treatment for hepatitis C.
    Berg T
    Clin Liver Dis; 2008 Aug; 12(3):507-28, vii-viii. PubMed ID: 18625426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eligibility criteria for antiviral therapy in HCV-positive patients: similar things to (almost) similar people.
    Giannini EG; Romagnoli P; Testa R
    Am J Gastroenterol; 2006 Feb; 101(2):406-7. PubMed ID: 16454854
    [No Abstract]   [Full Text] [Related]  

  • 12. Accurate hepatitis C virus genotyping and selection of optimal therapy: lessons from a St Petersburg strain infection.
    Knops E; Heger E; Koenig C; Moebius U; Lübke N; Kaiser R; Di Cristanziano V; Hüsgen L; Kocyigit C; Rupp J; Sierra S
    Clin Microbiol Infect; 2018 Apr; 24(4):440-441. PubMed ID: 29104172
    [No Abstract]   [Full Text] [Related]  

  • 13. Editorial commentary: Management of hepatitis C Virus in HIV-infected patients in the era of direct-acting antivirals.
    Zeremski M; Martinez AD; Talal AH
    Clin Infect Dis; 2014 Mar; 58(6):880-2. PubMed ID: 24336913
    [No Abstract]   [Full Text] [Related]  

  • 14. Introduction to hepatitis C virus (HCV) therapies special thematic issue.
    Meanwell NA; Watkins WJ
    J Med Chem; 2014 Mar; 57(5):1625-6. PubMed ID: 24484173
    [No Abstract]   [Full Text] [Related]  

  • 15. New therapeutic prospects in HCV treatment.
    Almasio PL; Ingrassia D; Vergara B; Filosto S
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):775-9. PubMed ID: 19053890
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel hepatitis C drugs in current trials.
    Kronenberger B; Welsch C; Forestier N; Zeuzem S
    Clin Liver Dis; 2008 Aug; 12(3):529-55, viii. PubMed ID: 18625427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of novel treatments for hepatitis C.
    Webster DP; Klenerman P; Collier J; Jeffery KJ
    Lancet Infect Dis; 2009 Feb; 9(2):108-17. PubMed ID: 19179226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical insights into enhanced management of patients with HCV infection with direct antiviral agents.
    Colombo M; Zeuzem S
    Dig Liver Dis; 2013 Sep; 45 Suppl 5():S313. PubMed ID: 24091108
    [No Abstract]   [Full Text] [Related]  

  • 19. Analysis of sequence configurations of the PKR-interacting HCV proteins from plasma and PBMC as predictors of response to interferon-alpha and ribavirin therapy in HIV-coinfected patients.
    Bolcic F; Bull L; Martinez L; Reynoso R; Salomon H; Arduino R; Barnett B; Quarleri J
    Intervirology; 2008; 51(4):261-4. PubMed ID: 18824873
    [No Abstract]   [Full Text] [Related]  

  • 20. Towards a better understanding of HCV transmission and course of infection.
    Berger A; Doerr HW
    Infection; 2004 Jun; 32(3):125. PubMed ID: 15188069
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.